1. Programmed Cell Death and Apoptosis Overview

Multicellular organisms maintain cellular homeostasis through a tightly regulated balance of cell proliferation, differentiation, and cell death. Cell death can be fundamentally categorised into accidental cell death (injury-induced) and programmed cell death (genetically controlled).

1.1 Classifying Cell Death

Accidental (unregulated) necrosis sits apart from the genetically controlled pathways. Programmed cell death itself branches into three distinct routes — apoptosis, autophagy, and regulated necrosis — each with its own trigger, machinery, and downstream consequence for surrounding tissue.

Figure: Classification of Cell Death. Cell death splits first into accidental (unregulated necrosis, triggered by physical or chemical trauma) and programmed cell death. Programmed cell death is genetically controlled and follows three distinct pathways: apoptosis (caspase-dependent), autophagy (lysosomal degradation), and regulated necrosis / necroptosis (death-receptor mediated).

1.2 Unregulated Necrosis

When a cell is subjected to extreme physical or chemical trauma (such as mechanical shear, severe hypoxia, or extreme thermal changes), it undergoes unregulated necrosis. This process is passive and marked by:

• Feature 1
  Loss of Membrane Integrity

  The plasma membrane ruptures, releasing cytosolic contents, lysosomal hydrolases, and intracellular debris into the surrounding interstitial fluid.

• Feature 2
  Inflammatory Response

  The sudden exposure of intracellular materials recruits leukocytes and phagocytic cells, triggering a highly localized, destructive inflammatory cascade that damages neighboring healthy tissues.

1.3 Regulated Necrosis (Necroptosis)

Contrary to historical belief, some necrotic events are genetically programmed and tightly regulated. This pathway, termed necroptosis, is mediated by death receptors and is activated when apoptotic caspases are blocked or fail to engage.

• Feature 1
  Mechanisms

  Necroptosis is negatively regulated by active caspases and requires the enzymatic activity of Receptor-Interacting Protein (RIP) kinases.

• Feature 2
  Physiological State

  Morphologically, necroptosis resembles necrosis (exhibiting cell swelling and membrane rupture), but it operates via a highly coordinated molecular pathway.

1.4 Autophagy

Autophagy is an intracellular catabolic degradation process where cytoplasm, damaged organelles, and protein aggregates are sequestered within double-membrane vesicles called autophagosomes. These vesicles transport their cargo to lysosomes, fusing to form autolysosomes, where acidic hydrolases enzymatically break down the cytoplasmic components to recycle metabolic building blocks.

1.5 Morphological and Biochemical Sequence of Apoptosis

Apoptosis is the most thoroughly characterized form of programmed cell death. It proceeds through a highly choreographed series of morphological and biochemical changes.

Figure: The Apoptotic Sequence. A stimulus such as DNA damage or FasL binding initiates cell shrinkage and chromatin condensation (pyknosis), followed by nuclear fragmentation (karyorrhexis), membrane blebbing, and apoptotic body formation. Phosphatidylserine exposure then flags the apoptotic bodies for rapid, non-inflammatory phagocytosis.

• Stage 1
  Cell Shrinkage

  Active dehydration and cytoskeletal collapse reduce cell volume.

• Stage 2
  Pyknosis

  Chromatin undergoes extreme condensation and aggregates against the nuclear envelope.

• Stage 3
  Karyorrhexis

  The nucleus fragments into multiple nucleosomal units.

• Stage 4
  Membrane Blebbing

  The cell surface displays irregular protrusion-like structures (blebs) due to actomyosin contraction forcing cytoplasm outward against a detached plasma membrane.

• Stage 5
  Apoptotic Body Formation

  The cell breaks apart into membrane-enclosed spheres containing intact, functional organelles and nuclear debris.

• Stage 6
  Rapid Phagocytosis

  Surrounding cells and resident macrophages recognize and engulf these apoptotic bodies before they can rupture.

1.6 Evasion of Inflammation

Unlike necrosis, apoptosis is completely non-inflammatory. This immunologically silent clearance is guaranteed by three distinct mechanisms:

• Mechanism 1
  Constituent Containment

  Apoptotic cells never release their cytoplasm or lysosomal enzymes into the surrounding interstitial tissue.

• Mechanism 2
  Rapid Clearance

  Nearby cells quickly phagocytose the intact apoptotic bodies.

• Mechanism 3
  Anti-inflammatory Signaling

  Engulfing cells are biochemically programmed not to release pro-inflammatory cytokines, maintaining tissue homeostasis.

1.7 Membrane Dynamics and the Phosphatidylserine Flip

The selective clearance of apoptotic cells is directed by changes in the lipid distribution of the plasma membrane.

Figure: Membrane Dynamics & the Phosphatidylserine Flip. In the normal state, ATP-dependent flippases keep phosphatidylserine (PS) restricted to the inner leaflet. Caspase activation cleaves flippases and activates calcium-dependent scramblases, driving PS to the outer leaflet — an "eat-me" signal recognized by PS-receptors on macrophages, triggering targeted, non-inflammatory engulfment.

• Normal
  Normal State

  The negatively charged phospholipid phosphatidylserine (PS) is restricted to the inner (cytosolic) leaflet of the plasma membrane, a state maintained by ATP-dependent flippases.

• Apoptotic
  Apoptotic State

  Upon caspase activation, flippases are cleaved and inactivated, while calcium-activated scramblases are stimulated. This drives the rapid transverse diffusion ("flip") of phosphatidylserine to the outer (extracellular) leaflet of the lipid bilayer.

• Signal
  The "Eat-Me" Signal

  Extracellularly exposed phosphatidylserine acts as a ligand for phagocytic receptors on neighboring macrophages, ensuring the targeted engulfment of the dying cell.

1.8 Comparative Overview: Modes of Cell Death

2. The Caspase Family of Proteases

The biochemical engine of apoptosis is driven by caspases (Cysteine-dependent aspartate-specific proteases). These endoproteases contain a critical catalytic cysteine residue within their active site and selectively cleave peptide bonds on the carboxyl-terminal side of specific aspartic acid residues.

Figure: Caspase Cleavage Site Specificity. Caspases recognize a specific aspartate (Asp) residue within the substrate's peptide backbone and cleave immediately on its carboxyl-terminal side, using a catalytic cysteine residue in the active site as the attacking nucleophile.

Beyond their roles in apoptotic cell death, caspases also participate in non-apoptotic cellular processes, including innate immune signaling, cellular proliferation, differentiation, and tumor suppression.

2.1 Subclassification of Caspases

Human caspases are classified into three functional subdivisions:

2.2 Domain Architecture of Human Procaspases

Caspases are synthesized as inactive monomeric or dimeric precursors called procaspases. Each precursor is built from an amino-terminal prodomain, a large catalytic subunit (~20 kDa), and a small catalytic subunit (~10 kDa) — only the length and motif content of the prodomain differs between subdivisions.

Figure: Procaspase Domain Architecture. Every procaspase shares a large (~20 kDa) and small (~10 kDa) catalytic subunit. Initiator and inflammatory caspases carry a long prodomain bearing a CARD or DED motif for recruitment into activating complexes; executioner caspases carry only a short prodomain and instead exist as pre-formed inactive dimers awaiting cleavage.

2.3 Prodomains and Catalytic Activation

• Motif
  Death Effector Domains (DED)

  Found in Caspase-8 and Caspase-10; allow binding to death receptors via adaptor proteins (e.g. FADD).

• Motif
  Caspase Recruitment Domains (CARD)

  Found in Caspase-2, Caspase-9, and inflammatory Caspase-1; allow association with upstream complexes (e.g. APAF-1).

• Structure
  Catalytic Subunits

  During activation, the linkers between the large subunit (~20 kDa) and small subunit (~10 kDa) are cleaved. Two large and two small subunits assemble to form an active heterotetrameric complex with two independent catalytic sites.

3. The Extrinsic (Death Receptor) Apoptotic Pathway

The extrinsic pathway of apoptosis is initiated by extracellular signaling molecules that bind to specialized transmembrane receptors on the target cell surface.

3.1 The Extrinsic Pathway Cascade

Figure: The Extrinsic Apoptotic Pathway. Homotrimeric FasL on a killer lymphocyte binds and trimerises Fas receptors on the target cell, clustering their intracellular Death Domains. FADD is recruited via DD–DD binding and in turn recruits procaspase-8 via DED–DED binding, forming the DISC. Auto-cleavage within the DISC activates caspase-8, which cleaves procaspase-3 and procaspase-7 into their active executioner forms, driving apoptosis.

3.2 Extracellular Ligand and Receptor Activation

• Ligand
  Fas Ligand (FasL)

  A homotrimeric transmembrane protein expressed on the surface of cytotoxic T-lymphocytes and natural killer (NK) cells.

• Receptor
  Fas Receptor (CD95 / APO-1)

  A member of the Tumor Necrosis Factor (TNF) receptor superfamily. It features an extracellular ligand-binding domain, a single-pass transmembrane domain, and an intracellular protein-interaction domain known as the Death Domain (DD).

• Assembly
  Ligand-induced Trimerisation

  The binding of homotrimeric FasL to monomeric Fas receptors drives their lateral clustering into active trimers.

3.3 Adaptor Recruitment and the DISC Complex

• Adaptor
  FADD (Fas-Associated Protein with Death Domain)

  Trimerised Fas receptors recruit FADD via homophilic interactions between their respective Death Domains (DD-to-DD binding).

• Recruitment
  Procaspase Recruitment

  FADD also contains an N-terminal Death Effector Domain (DED). This domain recruits the initiator procaspase (procaspase-8 or procaspase-10) through homophilic DED-to-DED interactions.

• Complex
  DISC Assembly

  The resulting complex of trimerised Fas receptors, FADD adaptors, and procaspases is called the Death-Inducing Signalling Complex (DISC).

• Activation
  Procaspase-8 Activation

  The high local concentration of procaspase-8 monomers within the DISC promotes their dimerization. This physical proximity triggers conformational changes and reciprocal auto-proteolytic cleavage, releasing active caspase-8 into the cytosol.

3.4 Downstream Execution

Active caspase-8 directly cleaves and activates the executioner procaspases-3 and procaspases-7. These executioner caspases target structural and regulatory proteins across the cell, executing the apoptotic program.

3.5 Regulation of the Extrinsic Pathway by c-FLIP

4. The Intrinsic (Mitochondrial) Apoptotic Pathway

The intrinsic pathway is activated by internal cellular stress signals, such as DNA damage, oxidative stress, hypoxia, and growth factor withdrawal. This pathway is also known as "apoptosis by neglect" because it often initiates when survival signals are lost.

4.1 The Intrinsic Pathway Cascade

Figure: The Intrinsic Apoptotic Pathway. Cellular stress triggers Bcl-2-family-regulated MOMP, releasing cytochrome c into the cytosol where it binds APAF-1. dATP hydrolysis drives a conformational shift that lets seven activated APAF-1 monomers assemble into the heptameric apoptosome, which recruits and activates procaspase-9 via CARD–CARD contacts. Active caspase-9 then cleaves procaspase-3 into its executioner form, driving apoptosis.

4.2 MOMP and Cytochrome c Release

The defining event of the intrinsic pathway is Mitochondrial Outer Membrane Permeabilisation (MOMP). When MOMP is triggered, cytochrome c (normally localized to the inner mitochondrial membrane and intermembrane space) is released into the cytosol.

4.3 Conformational Activation of APAF-1

• Step 1
  Resting State

  In healthy cells, APAF-1 (Apoptotic Protease Activating Factor-1) — the mammalian homologue of the C. elegans CED-4 protein — exists in the cytosol as an inactive monomer bound to dATP.

• Step 2
  Cytochrome c Binding

  Upon release into the cytosol, cytochrome c binds to APAF-1, triggering a conformational change that exposes its nucleotide-binding site.

• Step 3
  dATP Hydrolysis

  APAF-1 hydrolyses its bound dATP to dADP, prompting a second conformational change that exposes its oligomerization domain and its N-terminal Caspase Recruitment Domain (CARD).

4.4 Assembly of the Apoptosome

• Structure
  The Heptameric Ring

  Seven activated APAF-1 monomers self-assemble into a wheel-like heptameric ring called the apoptosome.

• Recruitment
  Procaspase-9 Recruitment

  The central core of the heptameric apoptosome exposes CARD domains that bind the CARD domain of the initiator procaspase-9.

• Activation
  Downstream Activation

  Once bound, procaspase-9 monomers undergo conformational activation through dimerization. Active caspase-9 then recruits and cleaves the executioner procaspase-3, triggering the catalytic cascade that dismantles the cell.

Figure: The Apoptosome. Seven activated APAF-1 monomers assemble radially around a central CARD hub to form the wheel-shaped apoptosome, which recruits procaspase-9 at its core. Neighboring APAF-1 subunits are held together by direct CARD-to-CARD contacts (inset).

4.5 Inhibitors of Apoptosis Proteins (IAPs)

4.6 Comparative Overview: Extrinsic vs. Intrinsic Pathways

5. Regulation by the Bcl-2 Protein Family

MOMP is controlled by the Bcl-2 (B-cell lymphoma/leukemia-2) family of proteins. These proteins are grouped into three distinct structural and functional classes based on their conserved Bcl-2 Homology (BH) domains.

5.1 Bcl-2 Family Structural Domain Architecture

Figure: Bcl-2 Family Domain Architecture. Anti-apoptotic guardians carry all four BH domains plus a membrane anchor. Pro-apoptotic effectors lack BH4 but retain BH1–BH3 and the anchor. BH3-only proteins are almost entirely unstructured, contributing only the short BH3 helix — and, in some members, a transmembrane tail.

5.2 The Three Functional Classes

• Guardian
  Anti-Apoptotic Members

  Proteins: Bcl-2, Bcl-xL, Bcl-w. Structure: Contain all four BH domains (BH1, BH2, BH3, BH4) and a C-terminal transmembrane anchor. Function: Bind and sequester pro-apoptotic proteins, protecting mitochondrial membrane integrity.

• Effector
  Pro-Apoptotic Effectors

  Proteins: Bax, Bak, Bok. Structure: Contain BH1, BH2, and BH3 domains along with a transmembrane domain. Function: Oligomerize to form macropores in the outer mitochondrial membrane, directly causing MOMP.

• Sensor
  Pro-Apoptotic BH3-Only Activators and Sensitisers

  Proteins: Bim, Puma, Noxa, Bik, Bad, Bid. Structure: Share only the short 9–16 amino acid BH3 domain. Function: Act as sensors of cellular stress, linking external stimuli to the core apoptotic machinery.

5.3 Mechanisms of BH3-Only Protein Action

BH3-only proteins drive cell death through two coordinated mechanisms.

Figure: BH3-Only Protein Action. Sensitiser BH3-only proteins neutralise anti-apoptotic guardians like Bcl-2 by competing for their hydrophobic binding pocket, displacing sequestered Bax/Bak; activator BH3-only proteins bind Bax/Bak directly, driving their oligomerization into a toroidal pore that permeabilises the outer mitochondrial membrane and releases cytochrome c.

• Mechanism 1
  Neutralisation of Anti-Apoptotic Proteins

  They bind to the hydrophobic pocket formed by the BH1, BH2, and BH3 domains of anti-apoptotic proteins (like Bcl-2), displacing sequestered Bax and Bak.

• Mechanism 2
  Direct Activation

  Activator BH3-only proteins (such as Bim and Bid) bind directly to Bax and Bak, inducing conformational changes that promote their oligomerization.

Once activated, Bax and Bak gather in the outer mitochondrial membrane, forming high-conductance toroidal pores that allow cytochrome c and other intermembrane proteins to leak into the cytosol.

6. The Biology of Cancer and Tumour Progression

A normal cell operates under strict regulatory controls governing cell division, differentiation, and survival. When these control networks fail, cells proliferate abnormally, forming a neoplasm (tumour).

6.1 Stages of Tumour Progression

Figure: Cancer Progression Timeline. An initiating mutation drives hyperplasia; further genetic and epigenetic hits produce dysplasia, then carcinoma in situ, still confined above the basement membrane. Protease-driven breach of the basement membrane marks invasive cancer, and intravasation/extravasation into blood or lymph completes the transition to metastasis.

• Stage 1
  Hyperplasia

  An initial mutation triggers excessive cell division, leading to an increased number of morphologically normal cells in a localized region.

• Stage 2
  Dysplasia

  Continued genetic and epigenetic changes alter cell shape, size, and tissue organization.

• Stage 3
  Carcinoma in situ

  Cells proliferate extensively and appear highly abnormal, but the tumor remains confined above the basal lamina (basement membrane).

• Stage 4
  Invasive Cancer (Malignancy)

  Cells acquire the ability to secrete proteases that degrade the extracellular matrix. They breach the basement membrane and invade the surrounding stroma.

• Stage 5
  Metastasis

  Cancer cells break away from the primary tumor, enter blood or lymphatic vessels, migrate to distant sites, and establish secondary colonies.

6.2 Benign versus Malignant Tumours

Tumours are classified as benign or malignant based on their cellular characteristics and behavior:

6.3 Etiological Classification of Malignancies

Malignant tumors are classified according to the embryonic tissue layer and cell type from which they originate:

• Epithelial
  Carcinomas

  Malignancies arising from epithelia that form protective cell layers (such as skin or gut linings), representing about 90% of human cancers.

• Glandular
  Adenocarcinomas

  Cancers originating from secretory epithelia (such as glandular tissues in the breast, lung, or prostate).

• Mesenchymal
  Sarcomas

  Malignancies arising from mesenchymal tissue (embryonic connective tissues, including bone, muscle, cartilage, and fat).

• Blood-Forming
  Hematopoietic Cancers

  Cancers of blood-forming organs and immune cells:

  • Leukemias: Cancers derived from white blood cell precursors in the bone marrow that circulate in the bloodstream.
  • Lymphomas: Solid tumors originating in lymphatic organs (such as lymph nodes).
  • Myelomas: Malignancies of mature, antibody-producing plasma cells in the bone marrow.
• Neural
  Neuroectodermal Cancers

  Cancers arising from components of the central and peripheral nervous systems (such as gliomas and neuroblastomas).

6.4 Clonal Evolution and Selection

Most human cancers display a monoclonal origin, meaning they arise from a single ancestral cell that acquired an initial driver mutation.

Figure: Clonal Evolution and Selection. Successive rounds of mutation generate branching subclones; those without a survival or proliferative advantage are outcompeted, while advantageous clones (growth advantage, then invasive properties) expand and accumulate further mutations, ultimately producing a fully transformed, heterogeneous tumor.

Tumour progression occurs through a multi-step process of transformation, driven by sequential genetic and epigenetic alterations:

• Step 1
  Initiation

  A cell undergoes an irreversible genetic change in a cancer-critical gene.

• Step 2
  Promotion (Clonal Expansion)

  The initiated cell proliferates in response to promoter signals, accumulating as a preneoplastic clone. This stage is typically slow and reversible.

• Step 3
  Progression

  Additional mutations occur within the expanding cell population.

• Step 4
  Clonal Selection

  Cells with mutations that confer a survival or proliferative advantage (such as resistance to apoptosis, independence from growth factors, or invasive capabilities) outcompete their neighbors. This ongoing selection drives the tumor toward a more aggressive, heterogeneous state.

7. Cellular Properties of Malignancy

As tumor cells progress, they acquire a set of characteristic properties that distinguish them from normal cells.

7.1 The Hallmarks of Malignant Transformation

Figure: Properties of Malignant Cells. Immortalisation, anchorage-independence, and loss of contact inhibition converge on angiogenesis induction, which in turn supports reduced growth factor dependence, active invasion and metastasis, and evasion of apoptosis — a self-reinforcing network of hallmark properties.

7.2 Acquired Properties in Detail

• Property 1
  Immortalisation

  Normal somatic cells divide a limited number of times before undergoing replicative senescence, a limit set by the progressive shortening of telomeres. Cancer cells upregulate telomerase, allowing them to maintain telomere length and divide indefinitely.

• Property 2
  Loss of Anchorage Dependence

  Normal cells must attach to a rigid extracellular matrix substratum to survive and divide (mediated by integrin signaling). Transformed cells survive and proliferate without anchorage, allowing them to grow in suspension or semisolid agar gels.

• Property 3
  Decreased Density-Dependent Inhibition of Proliferation

  Normal cells divide until they form a confluent monolayer, at which point depletion of local growth factors halts the cell cycle. Cancer cells continue to divide beyond this point, accumulating in dense clusters.

• Property 4
  Loss of Contact Inhibition

  When normal cells migrate and contact neighboring cells, they halt movement and form stable junctions. Cancer cells ignore these contact signals, crawling over one another in disorganized, multilayered patterns.

• Property 5
  Lower Growth Factor Requirements (Autocrine Stimulation)

  Normal cells require external growth factors to progress past the G1 restriction point. Cancer cells synthesize their own growth factors or express constitutively active mutant receptors, establishing self-sustaining autocrine stimulation loops.

• Property 6
  Evasion of Apoptosis

  Cancer cells bypass programmed cell death by mutating pro-apoptotic proteins (such as p53, Bax, or Bak) or upregulating anti-apoptotic proteins (such as Bcl-2 or XIAP), letting them survive under conditions of genomic instability or cellular stress.

• Property 7
  Invasiveness and Metastasis

  The dual capabilities that let cells leave the primary tumor and colonize distant sites:

  • Protease Secretion: Malignant cells secrete matrix metalloproteinases (MMPs) and plasminogen activators that degrade the basement membrane and extracellular matrix, clearing a path for stromal invasion.
  • Angiogenesis: As a tumor grows, its core becomes hypoxic. Cancer cells secrete angiogenic growth factors, such as Vascular Endothelial Growth Factor (VEGF) and Fibroblast Growth Factor (FGF), to stimulate the growth of new blood vessels into the tumor, supplying oxygen and nutrients.

7.3 The Metastatic Cascade

Figure: The Metastatic Cascade. Cells breach the stroma and intravasate into blood or lymphatic vessels, must survive circulatory shear stress and immune surveillance, then extravasate at a distant capillary bed and colonise the new tissue to form a vascularized secondary tumor.

• Step 1
  Intravasation

  Cancer cells cross the endothelial lining of blood or lymphatic vessels to enter the circulation.

• Step 2
  Survival in Circulation

  Cells must survive physical shear forces and immune surveillance within the bloodstream.

• Step 3
  Extravasation

  Cells adhere to the endothelial wall at a distant capillary bed and migrate out of the vessel into the target tissue.

• Step 4
  Colonisation

  The cells adapt to the microenvironment of the new tissue, establishing a vascularized secondary tumor.

8. Genetics of Cancer-Critical Genes

Cancer is fundamentally a genetic disease driven by mutations in cancer-critical genes, which are classified into two major categories based on their normal role in regulating the cell cycle.

8.1 Classifying Cancer-Critical Genes

Proto-oncogenes act as the "gas pedal" of the cell cycle, while tumour suppressor genes act as the "brake system." Mutation of either class — through opposite mechanisms — can drive a cell toward malignant transformation.

Figure: Classification of Cancer-Critical Genes. Proto-oncogenes acquire dominant gain-of-function mutations that convert them into hyperactive oncogenes, directly driving transformation. Tumour suppressor genes instead require recessive loss-of-function of both alleles ("two hits"), and are further subdivided into gatekeepers (direct checkpoint control) and caretakers (genomic maintenance).

8.2 Proto-oncogenes versus Tumour Suppressor Genes

These two gene classes act through opposite mutational logic — one is switched on, the other is switched off — yet both converge on the same outcome of uncontrolled proliferation.

8.3 Gatekeepers versus Caretakers

Tumour suppressor genes are further subclassified based on their physiological role in preventing malignancy.

• Direct Control
  Gatekeepers

  Genes that directly regulate cell cycle progression or drive apoptosis (such as TP53, RB1, and APC). They act as the molecular checkpoints of the cell.

• Maintenance
  Caretakers

  Genes responsible for maintaining genomic stability, chromosome segregation, and DNA repair (such as BRCA1, BRCA2, MSH2, and MLH1). When caretakers are lost, mutation rates across the entire genome rise, accelerating the inactivation of gatekeeper genes.

9. Mechanisms of Proto-oncogene Activation

A proto-oncogene can be converted into an oncogene through several distinct genetic mechanisms, all of which converge on the same result: protein overexpression or constitutive, ligand-independent activity.

9.1 The Five Activation Pathways

Point mutation and gene amplification act on a single gene locus; chromosomal translocation and retroviral insertion instead relocate a proto-oncogene into a new transcriptional context.

Figure: Proto-oncogene Activation Pathways. Point mutation and gene amplification act on a single locus to create a hyperactive or overexpressed protein. Chromosomal translocation relocates a proto-oncogene into a new regulatory context — either under a strong tissue-specific enhancer (Burkitt's lymphoma) or fused in-frame to a partner gene to create a constitutively active kinase (CML). Retroviral insertion drives unregulated transcription from a viral LTR promoter inserted upstream of the proto-oncogene's exons.

9.2 Point Mutation and Gene Amplification

• Single-Locus
  Point Mutation

  A single nucleotide substitution can alter a single amino acid in the encoded protein, rendering it constitutively active. Example: Ras G-protein signal transducers (HRAS, KRAS, and NRAS). Point mutations that block intrinsic GTPase activity lock Ras in its active, GTP-bound conformation, sending continuous growth signals to downstream MAPK cascades.

• Dosage Effect
  Gene Amplification

  During abnormal DNA replication, localized genomic regions can undergo repeated rounds of duplication, creating dozens of extra copies of a gene. Example: Amplification of the MYCN proto-oncogene in neuroblastoma. High copy numbers of MYCN lead to extreme protein overexpression, a state associated with rapid tumor progression and poor clinical outcomes.

9.3 Chromosomal Translocation

Physical rearrangement and reciprocal exchange between non-homologous chromosomes can drive oncogenesis in two distinct ways.

• t(8;14)(q24;q32)
  Burkitt's Lymphoma

  This translocation moves the MYC proto-oncogene from chromosome 8 to the immunoglobulin heavy chain (IgH) locus on chromosome 14. B-lymphocyte-specific enhancers in the IgH locus drive massive, uncontrolled transcription of the normal MYC protein, driving B-cell proliferation.

• t(9;22)(q34;q11.2)
  Chronic Myelogenous Leukemia (CML)

  This translocation fuses the ABL tyrosine kinase gene on chromosome 9 with the BCR gene on chromosome 22, creating a small chimeric chromosome known as the Philadelphia chromosome (Ph¹) that carries a novel BCR-ABL fusion gene. The encoded fusion protein exhibits hyperactive, ligand-independent tyrosine kinase activity, driving the proliferation of myeloid stem cells.

9.4 Insertional Activation by Retroviruses

When a non-defective retrovirus infects a host cell, it integrates its viral genome randomly into the host DNA. If a retrovirus like the Avian Leukosis Virus (ALV) integrates its double-stranded DNA copy upstream of or within the MYC proto-oncogene, the strong promoter and enhancer elements within the viral Long Terminal Repeats (LTRs) drive high-level, unregulated transcription of host MYC exons — bypassing the cell's normal transcriptional checkpoints.

9.5 Specific Chromosomal Aberrations in Cancer

10. Molecular Biology of Key Tumour Suppressor Genes

Tumour suppressor genes act as the cellular brakes that halt the cell cycle in response to cellular stress. Their molecular mechanisms differ sharply from proto-oncogenes, since it is the loss — not the gain — of function that is oncogenic.

10.1 The TP53 (p53) Pathway

The TP53 gene (located at chromosome 17p13.1) is mutated in more than 50% of all human cancers. The p53 protein acts as a homotetrameric transcription factor that coordinates cell cycle arrest, DNA repair, metabolic adaptation, autophagy, and apoptosis.

Figure: p53 Monomeric Domain Architecture. Each p53 monomer runs from an N-terminal transactivation domain through a proline-rich linker to the large core DNA-binding domain — the site of the overwhelming majority of cancer-associated missense mutations — and terminates in the C-terminal tetramerisation domain required for assembly of the active homotetramer.

10.2 The Retinoblastoma (RB1) Pathway

The RB1 gene (located at chromosome 13q14) encodes the Rb pocket protein, which controls progression past the G1 restriction point by physically sequestering the E2F transcription factor.

Figure: The Retinoblastoma (Rb) Checkpoint Gate. In the hypo-phosphorylated state, active Rb binds and represses E2F, blocking S-phase gene expression and holding the cell in G1. Mitogen-driven Cyclin D1-CDK4/6 complexes phosphorylate Rb at multiple residues, triggering a conformational change that releases E2F to transcribe Cyclin E, CDK2, and the S-phase DNA replication machinery — committing the cell to divide.

Active State (Hypo-phosphorylated): In G0 and early G1, Rb is unphosphorylated or hypo-phosphorylated. It binds to the E2F family of transcription factors, recruiting histone deacetylases (HDACs) to repress the promoters of genes required for DNA replication. Inactive State (Hyper-phosphorylated): In response to mitogen signaling, Cyclin D1-CDK4/6 complexes phosphorylate Rb, releasing E2F to drive S-phase transcription. Malignant Inactivation: Deletions or loss-of-function mutations in RB1 prevent E2F sequestration, allowing cells to enter S-phase continuously without external growth signals.

10.3 BRCA1 and BRCA2

Located at 17q21 and 13q12.3 respectively, BRCA1 and BRCA2 are caretaker genes that maintain genomic integrity.

• Mechanism
  Homologous Recombination Repair

  BRCA1 and BRCA2 coordinate the repair of double-strand DNA breaks via homologous recombination (HR), a high-fidelity, template-directed repair pathway.

• Pathology
  Loss of Function

  Cells lacking functional BRCA1 or BRCA2 cannot execute homologous recombination. Instead, they rely on error-prone repair pathways like Non-Homologous End Joining (NHEJ), leading to chromosomal rearrangements and a high risk of breast and ovarian cancers.

10.4 Common Tumour Suppressor Genes

11. Retinoblastoma and Knudson's Two-Hit Hypothesis

The study of retinoblastoma, a rare childhood tumor of the retina, led to the development of Alfred Knudson's "Two-Hit" Hypothesis, which explains the genetic basis of hereditary and sporadic cancers.

11.1 Knudson's Two-Hit Model of Retinoblastoma

Because RB1 mutations are recessive at the cellular level, both copies of the gene must be inactivated before a retinal cell escapes growth control. Whether the first of those two "hits" is inherited or acquired determines the entire clinical picture.

Figure: Knudson's Two-Hit Model of Retinoblastoma. In hereditary retinoblastoma, every cell already carries one inherited mutant rb1 allele, so only a single somatic "second hit" is needed in any retinal cell — making bilateral, early, multi-focal tumors likely. In sporadic retinoblastoma, both alleles must be independently inactivated by chance within the same cell lineage, a far rarer event that produces a single, later-onset, unilateral tumor.

11.2 Hereditary (Familial) Retinoblastoma

• First Hit
  Inherited Germline Mutation

  The individual inherits one mutated, inactive rb1⁻ allele in the germline from an affected parent. Consequently, every cell in the body is heterozygous for the mutation.

• Second Hit
  Somatic Loss of the Remaining Allele

  During early childhood, a spontaneous somatic mutation inactivates the remaining wild-type RB1⁺ allele in a developing retinal cell.

• Presentation
  Bilateral, Multi-focal, Early Onset

  Because all retinal cells already carry the first mutation, the probability of a second hit occurring in at least one cell in both eyes is high. This leads to bilateral, multi-focal tumors that present early in life.

11.3 Sporadic (Non-Hereditary) Retinoblastoma

• First Hit
  Two Normal Alleles at Birth

  The individual inherits two normal RB1⁺ alleles.

• Both Hits Somatic
  Two Independent Somatic Mutations

  To develop retinoblastoma, a single retinal progenitor cell must acquire two independent, spontaneous somatic mutations to inactivate both alleles.

• Presentation
  Unilateral, Unifocal, Late Onset

  Because the probability of two independent somatic mutations occurring in the same cell lineage is low, sporadic retinoblastoma is rare, presents later in childhood, and is almost always unilateral and unifocal.

12. Carcinogenesis and Tumour Virology

The transformation of normal cells into cancer cells is driven by exposure to agents that damage DNA or stimulate cell proliferation — chemical, physical, and biological.

12.1 Three Classes of Carcinogens

• Physical
  Physical Carcinogens

  Radiation (such as UV-ray and gamma-ray) that directly damages DNA, inducing double-strand breaks or pyrimidine dimers.

• Chemical — Direct
  Direct-acting Carcinogens

  Electrophilic compounds that react directly with DNA nucleophiles without prior metabolic modification.

• Chemical — Indirect
  Indirect-acting Carcinogens (Pro-carcinogens)

  Chemically inert compounds that require metabolic activation by host enzymes to become mutagenic.

• Biological
  Biological Carcinogens

  Oncoviruses, bacteria (e.g., Helicobacter pylori), and parasites that induce chronic inflammation or introduce oncogenic proteins.

12.2 Metabolic Activation of Aflatoxin B1

Aflatoxin B1 is a potent indirect-acting chemical mycotoxin produced by the molds Aspergillus flavus and Aspergillus parasiticus, which grow on stored grains and nuts.

Figure: Metabolic Activation of Aflatoxin B1. Ingested Aflatoxin B1 is oxidised by hepatic Cytochrome P450 enzymes into the highly reactive aflatoxin-2,3-epoxide, which covalently attacks the N7 position of guanine residues. During DNA replication, polymerases mispair the bulky adducted guanine with adenine, producing a signature G-to-T transversion that targets codon 249 of TP53 and drives hepatocellular carcinoma.

12.3 Tumour Promoters versus Initiators

The chemical induction of cancer is a multi-step process requiring both initiator and promoter signals.

• Irreversible
  Tumour Initiators

  Mutagenic agents (such as chemical carcinogens) that cause permanent, irreversible DNA damage.

• Reversible
  Tumour Promoters

  Non-mutagenic compounds that stimulate cellular proliferation without altering DNA sequences. Example: Phorbol esters (such as TPA) structurally mimic diacylglycerol (DAG). They bind and activate Protein Kinase C (PKC), triggering mitogenic cascades that drive the expansion of initiated cell clones.

12.4 DNA Oncoviruses

DNA oncoviruses carry viral oncogenes that encode proteins that bind and inactivate host tumor suppressor proteins, disrupting cell cycle checkpoints.

Figure: Oncoprotein Interception of Host Checkpoints. High-risk HPV strains express E6, which targets p53 for ubiquitin-mediated proteasomal degradation, and E7, which binds and displaces Rb to free E2F. Adenoviruses achieve the same dual checkpoint knockout using two different proteins — E1B against p53 and E1A against Rb — illustrating convergent evolution toward disabling the same two gatekeeper pathways.

• HPV-16 / HPV-18
  Human Papillomavirus (HPV)

  Associated with cervical, anogenital, and oropharyngeal cancers. E6 binds host p53, recruiting the E6AP E3 ubiquitin ligase to target p53 for proteasomal degradation, blocking DNA damage checkpoints. E7 binds host Rb, displacing E2F to drive cell entry into S-phase in the absence of mitogen signals.

• Model System
  Adenoviruses

  Express E1A (which binds and inactivates Rb) and E1B (which binds and inactivates p53), driving cellular transformation in model systems.

• Chronic Inflammation
  Hepatitis B Virus (HBV)

  Promotes hepatocellular carcinoma by inducing chronic inflammation and expressing the HBx protein, which disrupts DNA repair and cell cycle control.

• Lymphoproliferative
  Epstein-Barr Virus (EBV)

  Linked to Burkitt's lymphoma and nasopharyngeal carcinoma.

• Vascular
  Kaposi's Sarcoma-Associated Herpesvirus (KSHV/HHV-8)

  Linked to Kaposi's sarcoma.

12.5 RNA Oncoviruses and Retroviral Transduction

RNA oncoviruses, primarily retroviruses, can transform host cells through retroviral transduction.

Figure: Evolution of Retroviral v-src. The host c-src proto-oncogene contains a C-terminal exon encoding the regulatory Tyrosine-527 residue. During retroviral transduction into an ancestral Rous Sarcoma Virus genome, this regulatory exon was lost, leaving the resulting v-src oncogene permanently locked in its active, kinase-signaling conformation.

• 1911, Peyton Rous
  Rous Sarcoma Virus (RSV)

  The first retrovirus shown to cause cancer. RSV carries an oncogene called v-src, which encodes a hyperactive tyrosine kinase.

• Loss of Regulation
  v-src versus c-src

  Normal host genomes contain a highly conserved proto-oncogene called c-src (cellular src). During viral replication in an ancestral host cell, the retrovirus integrated near the c-src locus; upon excision, the virus incorporated c-src into its own genome (transduction). During transduction, the gene lost its final exon, which encodes the critical regulatory residue Tyrosine-527. In normal cells, phosphorylation of Tyrosine-527 by Csk keeps c-src in an inactive conformation — lacking this site, the viral v-src protein is constitutively active, driving cell transformation and sarcoma development.